News | Oncology Diagnostics | December 11, 2015

Data from time-efficiency study presented at RSNA 2015 demonstrates increased patient throughput, workflow efficiencies

Lymphoseek, RSNA 2015, clinical study, sentinel lymph node mapping, SLN

Image courtesy of Navidea Biopharmaceuticals


December 11, 2015 — Navidea Biopharmaceuticals Inc. announced that results from an investigator-initiated imaging study demonstrated Lymphoseek (technetium Tc 99m tilmanocept) injection reduced imaging time by more than 50 percent in sentinel lymph node biopsy procedures in malignant melanoma compared to Tc99m sulfur colloid (SC).

This finding suggests hospitals and oncology treatment teams can achieve greater patient throughput and workflow efficiencies utilizing Lymphoseek. Results of the study — conducted at the Thomas Jefferson University Hospitals and led by Charles M. Intenzo, M.D., professor of radiology, director, nuclear medicine and molecular imaging in the Department of Radiology — were presented at the Radiological Society of North America annual meeting (RSNA 2015) in Chicago.

A total of 34 consecutive patients with malignant melanoma underwent sentinel lymph node (SLN) mapping with Lymphoseek. Patients received the Lymphoseek dose in four intradermal administrations around the tumor site. Images were acquired at intervals up to 40 minutes after injection, which is the department’s standard-of-care protocol used for Tc99m Sulfur Colloid (SC) procedures. This site’s previous experience showed that SC injections required 40 to 45 minutes after injection for visualization of all lymph nodes in patients with malignant melanoma.

Using Lymphoseek, the results show that in all 34 patients, all lymph nodes seen in the final 40-minute image were identified in the 20-minute image, providing rapid and stable localization and identification of the sentinel nodes. The study concludes that in malignant melanoma, SLN mapping with Lymphoseek involves a total imaging time of 20 minutes, which is one-half of the time required for Tc99m SC. From a clinical perspective, the authors conclude that utilizing Lymphoseek is more time-efficient than SC by facilitating patient throughput and expediting subsequent transport to the operating room.

For more information: www.lymphoseek.com


Related Content

News | Pediatric Imaging

May 2, 2024 — Head and abdominal trauma is a leading cause of death for children. About 1%–2% of children who come to ...

Time May 02, 2024
arrow
News | Prostate Cancer

May 2, 2024 — GT Medical Technologies, Inc. (GT MedTech), a medical device company with the mission of improving the ...

Time May 02, 2024
arrow
Feature | Radiology Business

Beginning this spring, ITN will begin sending out a bi-monthly survey to our readers on a variety of topics, which we ...

Time May 02, 2024
arrow
News | Radiation Therapy

May 1, 2024 — Sun Nuclear, a Mirion Medical company, today announced the upcoming version 5.0 release of its SunCHECK ...

Time May 01, 2024
arrow
News | Breast Imaging

April 30, 2024 — Use of publicly available large language models (LLMs) resulted in changes in breast imaging reports ...

Time April 30, 2024
arrow
News | Proton Therapy

April 29, 2024 — Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today ...

Time April 29, 2024
arrow
Feature | Breast Imaging | By Christine Book

From implementing artificial intelligence effectively, advocating for radiologists, and working tirelessly to expand ...

Time April 29, 2024
arrow
News | Radiology Business

April 23, 2024 — A diverse writing group, led by authors at the University of Toronto, have developed an approach for ...

Time April 23, 2024
arrow
News | Artificial Intelligence

April 19, 2024 — Large language model GPT-4 matched the performance of radiologists in detecting errors in radiology ...

Time April 22, 2024
arrow
News | Computed Tomography (CT)

April 22, 2024 — A new study showed that a non-invasive imaging test can help identify patients with coronary artery ...

Time April 22, 2024
arrow
Subscribe Now